Evidence map›Paper›PMID 41013205›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

YULINK deficiency promotes cell death under glucose restriction in HCC cells in association with GLUT1-mediated glycolysis.

Yi-Chia Wu, Tsai-Hsien Hung, Wei-Ting Thomas Wang, Ming-Wei Kuo, Yuh-Jin Liang, Yur-Ren Kuo, Ming-Feng Hou, Chung-Sheng Lai, Alice L Yu, John Yu

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi-Chia Wu *Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan.
Tsai-Hsien Hung *Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan.
Wei-Ting Thomas WangDivision of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ming-Wei KuoInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan.
Yuh-Jin LiangInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan.
Yur-Ren KuoRegenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ming-Feng HouDivision of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chung-Sheng LaiDivision of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Alice L YuInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan.
John YuInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linko, Taoyuan, Taiwan. johnyu@gate.sinica.edu.tw.

Funding

Chang Gung Memorial Hospital, Linkou CMRPG3Q0121Chang Gung Memorial Hospital, Linkou OMRPG3C0048Ministry of Science and Technology, Taiwan MOST 103-2628-B-037-002-MY3Ministry of Science and Technology, Taiwan MOST 109-2321-B-182A-005Ministry of Science and Technology, Taiwan NSTC 113-2314-B-182A-154
6 · The paper itself

Abstract

backgroundThrough evolutionary genomics analysis, we identified Yulink (MIOS, Entrez Gene: 54,468), a highly conserved gene encoding an 875 amino acid protein with diverse functions in humans. Given the importance of accelerated glycolysis in hepatocellular carcinoma (HCC), we explored the expression and function of Yulink in HCC cells and analyzed clinicopathological data to unveil its impact on patient survival.

methodsClinicopathological data from 184 patients with resectable HCC were mined to establish a correlation between Yulink expression and patient survival. We employed reverse transcription quantitative polymerase chain reaction (RT-qPCR) to assess Yulink expression in the tumor tissues. Various assays, including Western blotting, migration, MTT, cell cycle, immunofluorescence, oxidative stress, tumorigenesis, glucose uptake, glycolytic function, proximity ligation, and immunoprecipitation, were conducted on Huh7 cells to identify the regulatory mechanisms under glucose restriction.

resultsComparative evolutionary genomics analysis revealed that patients with high Yulink expression had significantly shorter relapse-free survival (RFS) and overall survival (OS) (P < 0.0001 and = 0.0015, respectively). Multivariable Cox regression analysis identified Yulink expression as an independent unfavorable predictor of RFS (HR, 2.63; 95% CI, 1.58-4.38; P < 0.001) in HCC. Furthermore, Yulink expression positively correlated with Huh7 migration and survival, especially in response to glucose restriction. Yulink deficiency enhanced glucose restriction-induced cell death, likely due to increased reactive oxygen species (ROS) and DNA damage, with a failure of ATM-CHK2 activation. Huh7 xenografts with Yulink suppression exhibited delayed tumorigenesis in immunocompromised nude mice. Importantly, proximity Ligation assays and immunoprecipitation demonstrated that Yulink colocalized and interacted with glucose transporter 1 (GLUT1). Knockdown of Yulink not only suppressed GLUT1 expression, but also disrupted GLUT1 translocation from the cytosol to the cell membrane, resulting in downregulated glucose uptake and glycolysis.

conclusionsOur results underscore the protective role of Yulink in HCC survival under glucose restriction and its pivotal function in glucose metabolism, suggesting a mechanistic link between lower Yulink expression and higher survival in patients with HCC.

Indexed as

Carcinoma, HepatocellularGlucoseGlucose Transporter Type 1GlycolysisLiver NeoplasmsAnimalsCell DeathCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedGlucoseGlucose Transporter Type 1SLC2A1 protein, humanGlucose restrictionGlucose transporter isoform 1Hepatocellular carcinomaYULINK

Identifiers

PMID41013205
PMCPMC12465497

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.